Akari Therapeutics (AKTX) Accounts Payables (2011 - 2026)
Akari Therapeutics recorded quarterly Accounts Payables of $8.6 million in Q1 2026, down 1.47% quarter-over-quarter from $8.8 million in Q4 2025, and down 33.87% year-over-year from $13.1 million in Q1 2025.
Akari Therapeutics' Accounts Payables history runs 16 years deep, the most recent figure standing at $8.6 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 33.87% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (down 33.87% YoY), while the FY2025 annual figure was $8.8 million, down 29.31% from the prior year.
- Accounts Payables came in at $8.6 million for Q1 2026 at Akari Therapeutics, down from $8.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $13.1 million in Q1 2025 to a low of $78814.0 in Q2 2023.
- A 5-year average of $6.1 million and a median of $4.7 million in 2024 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables surged 15910.14% in 2022 and slumped 95.18% in 2023, its largest moves.
- Akari Therapeutics' Accounts Payables stood at $947000.0 in 2022, then soared by 76.45% to $1.7 million in 2023, then jumped by 642.49% to $12.4 million in 2024, then fell by 29.31% to $8.8 million in 2025, then slipped by 1.47% to $8.6 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $8.6 million, $8.8 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 80.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.64 Mn |
| Dec 31, 2025 | 8.77 Mn |
| Sep 30, 2025 | 10.84 Mn |
| Jun 30, 2025 | 11.61 Mn |
| Mar 31, 2025 | 13.07 Mn |
| Dec 31, 2024 | 12.41 Mn |
| Sep 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 4.69 Mn |
| Mar 31, 2024 | 3.21 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Dec 31, 2022 | 947,000.00 |
| Jun 30, 2022 | -147,136.00 |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 5,915.00 |
| Sep 30, 2021 | 1.92 Mn |
| Jun 30, 2021 | 1.69 Mn |
| Mar 31, 2021 | 2.83 Mn |
| Dec 31, 2020 | 5,058.00 |
| Sep 30, 2020 | 2.41 Mn |
| Jun 30, 2020 | 2.19 Mn |
| Mar 31, 2020 | 966,059.00 |
| Dec 31, 2019 | 5,350.00 |
| Sep 30, 2019 | 1.32 Mn |
| Jun 30, 2019 | 1.48 Mn |
| Mar 31, 2019 | 1.76 Mn |
| Dec 31, 2018 | 2,987.00 |
| Sep 30, 2018 | 1.40 Mn |
| Jun 30, 2018 | 2.00 Mn |
| Mar 31, 2018 | 2.38 Mn |
| Dec 31, 2017 | 6,591.00 |
| Sep 30, 2017 | 1.94 Mn |
| Jun 30, 2017 | 2.84 Mn |
| Mar 31, 2017 | 924,480.00 |
| Dec 31, 2016 | 3,987.00 |
| Sep 30, 2016 | 1.31 Mn |
| Jun 30, 2016 | 1.92 Mn |
| Mar 31, 2016 | 625,372.00 |
| Dec 31, 2015 | 4,546.00 |
| Jun 30, 2015 | 331,000.00 |
| Mar 31, 2015 | 614,000.00 |
| Dec 31, 2014 | 39,236.00 |
| Dec 31, 2013 | 652,000.00 |
| Dec 31, 2012 | 1.26 Mn |
| Dec 31, 2011 | 1.38 Mn |